Development of a Radiofluorinated Adenosine A2B Receptor Antagonist as Potential Ligand for PET Imaging
Authors:
- Marcel LindemannMLMarcel Lindemann
- Rareş-Petru MoldovanRMRareş-Petru Moldovan
- Sonja HinzSHSonja Hinz
- Winnie Deuther-ConradWDWinnie Deuther-Conrad
- Daniel GündelDaniel Gündel
- Sladjana Dukic-StefanovicSDSladjana Dukic-Stefanovic
- Magali ToussaintMagali Toussaint
- Rodrigo TeodoroRodrigo Teodoro
- Jörg SteinbachJSJörg Steinbach
- Peter BrustPBPeter Brust
- Christa E. MüllerCMChrista E. Müller
Open Access
- 30 April 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (9) , 3197
Abstract
The adenosine A2B receptor has been proposed as a novel therapeutic target in cancer, as its expression is drastically elevated in several tumors and cancer cells. Noninvasive molecular imaging via positron emission tomography (PET) would allow the in vivo quantification of this receptor in pathological processes and most likely enable the identification and clinical monitoring of respective cancer therapies. On the basis of a bicyclic pyridopyrimidine-2,4-dione core structure, the new adenosine A2B receptor ligand 9 was synthesized, containing a 2-fluoropyridine moiety suitable for labeling with the short-lived PET radionuclide fluorine-18. Compound 9 showed a high binding affinity for the human A2B receptor (Ki(A2B) = 2.51 nM), along with high selectivities versus the A1, A2A, and A3 receptor subtypes. Therefore, it was radiofluorinated via nucleophilic aromatic substitution of the corresponding nitro precursor using [18F]F-/K2.2.2./K2CO3 in DMSO at 120 °C. Metabolic studies of [18F]9 in mice revealed about 60% of radiotracer intact in plasma at 30 minutes p.i. A preliminary PET study in healthy mice showed an overall biodistribution of [18F]9, corresponding to the known ubiquitous but low expression of the A2B receptor. Consequently, [18F]9 represents a novel PET radiotracer with high affinity and selectivity toward the adenosine A2B receptor and a suitable in vivo profile. Subsequent studies are envisaged to investigate the applicability of [18F]9 to detect alterations in the receptor density in certain cancer-related disease models.Keywords
Funding Information
- Bundesministerium für Forschung, Technologie und Raumfahrt (Neuroallianz D11B)
This publication has 27 references indexed in Scilit:
- International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An UpdatePharmacological Reviews, 2011
- Discovery of LAS101057: A Potent, Selective, and Orally Efficacious A2B Adenosine Receptor AntagonistACS Medicinal Chemistry Letters, 2010
- Discovery of potent and selective bicyclic A2B adenosine receptor antagonists via bioisosteric amide replacementBioorganic & Medicinal Chemistry Letters, 2010
- Discovery of N-(5,6-diarylpyridin-2-yl)amide derivatives as potent and selective A2B adenosine receptor antagonistsBioorganic & Medicinal Chemistry Letters, 2010
- 1-Alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: Development and Characterization of Adenosine A2BReceptor Antagonists and a New Radioligand with Subnanomolar Affinity and Subtype SpecificityJournal of Medicinal Chemistry, 2009
- Micelles as separation media in high-performance liquid chromatography and high-performance capillary electrophoresis: overview and perspectiveJournal of Chromatography A, 1997
- Palladium(0)-Catalyzed Cross-Coupling Reaction of Alkoxydiboron with Haloarenes: A Direct Procedure for Arylboronic EstersThe Journal of Organic Chemistry, 1995
- Synthese von substituierten 2‐AminonicotinonitrilenArchiv der Pharmazie, 1994
- A new stereospecific cross-coupling by the palladium-catalyzed reaction of 1-alkenylboranes with 1-alkenyl or 1-alkynyl halidesTetrahedron Letters, 1979
- Stereoselective synthesis of arylated (E)-alkenes by the reaction of alk-1-enylboranes with aryl halides in the presence of palladium catalystJournal of the Chemical Society, Chemical Communications, 1979